Navigation Links
Most-used diabetes drug works in different way than previously thought
Date:1/6/2013

PHILADELPHIA - A team, led by senior author Morris J. Birnbaum, MD, PhD, the Willard and Rhoda Ware Professor of Medicine, with the Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, found that the diabetes drug metformin works in a different way than previously understood. Their research in mice found that metformin suppresses the liver hormone glucagon's ability to generate an important signaling molecule, pointing to new drug targets. The findings were published online this week in Nature.

For fifty years, one of the few classes of therapeutics effective in reducing the overactive glucose production associated with diabetes has been the biguanides, which includes metformin, the most frequently prescribed drug for type 2 diabetes. The inability of insulin to keep liver glucose output in check is a major factor in the high blood sugar of type 2 diabetes and other diseases of insulin resistance.

"Overall, metformin lowers blood glucose by decreasing liver production of glucose," says Birnbaum. "But we didn't really know how the drug accomplished that."

Imperfectly Understood

Despite metformin's success, its mechanism of action remained imperfectly understood. About a decade ago, researchers suggested that metformin reduces glucose synthesis by activating the enzyme AMPK. But this understanding was challenged by genetic experiments in 2010 by collaborators on the present Nature study. Coauthors Marc Foretz and Benoit Viollet from Inserm, CNRS, and Universit Paris Descartes, Paris, found that the livers of mice without AMPK still responded to metformin, indicating that blood glucose levels were being controlled outside of the AMPK pathway.

Taking another look at how glucose is regulated normally, the team knew that when there is no food intake and glucose decreases, glucagon is secreted from the pancreas to signal the liver to produce glucose. They then asked if metformin works by stopping the glucagon cascade.

The Nature study describes a novel mechanism by which metformin antagonizes the action of glucagon, thus reducing fasting glucose levels. The team showed that metformin leads to the accumulation of AMP in mice, which inhibits an enzyme called adenylate cyclase, thereby reducing levels of cyclic AMP and protein kinase activity, eventually blocking glucagon-dependent glucose output from liver cells.

From this new understanding of metformin's action, Birnbaum and colleagues surmise that adenylate cyclase could be a new drug target by mimicking the way in which it is inhibited by metformin. This strategy would bypass metformin's affect on a cell's mitochondria to make energy, and possibility avoid the adverse side effects experienced by many people who take metformin, perhaps even working for those patients resistant to metformin.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert  

Related biology news :

1. UCSB researchers perform pioneering research on Type 2 diabetes
2. NTU study finds ways to prevent muscle loss, obesity and diabetes
3. Notre Dame research may have important implications for combating diabetes
4. University of Chicagos Graeme Bell receives international diabetes prize
5. Joslin researchers increase understanding of genetic risk factor for type 1 diabetes
6. Arginine and proline enriched diet may speed wound healing in diabetes
7. Diabetes Management Provider ActiveCare Announces Cost Savings Of Over $4,000 Per Year Per Diabetic Member
8. Purple corn compound may aid in developing future treatments for Type 2 diabetes, kidney disease
9. Risk of developing diabetes higher in neighborhoods that arent walk-friendly: Study
10. Cystic fibrosis disrupts pancreas two ways in CF-related diabetes
11. Shedding new light on one of diabetes most dangerous complications
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Most-used diabetes drug works in different way than previously thought
(Date:2/3/2016)... --> --> ... Fingerprint Identification System Market by Component (Hardware and Software), ... Finance, Government, Healthcare, and Transportation) and Geography - Global ... expected to be worth USD 8.49 Billion by 2020 ... 2020. The transformation and technology evolution from the manual ...
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... Conn. , Feb. 8, 2016  NanoViricides, Inc. (NYSE MKT: ... its CEO, Eugene Seymour , MD, MPH, will present information ... at the Waldorf-Astoria Hotel in New York City ... will be in the Windsor Room at 5:30PM EST. Registered attendees ... New York City . --> ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, ... Excellence in Education Sponsors Teacher Training Program , Bite of Science Dinner Event ... Center for Excellence in Education (CEE) will sponsor a Bite of Science professional ...
(Date:2/5/2016)... SYDNEY , Feb. 5, 2016 Australian-US drug ... ), announced today the appointment of a new Chairman, Mr ... Bryce Carmine , effective immediately. James Garner ... an Executive Director and former Acting CEO, Mr Iain ... a Non-Executive Director. --> James Garner , has ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... Club, takes place February 5-6 at the University’s student center, Kehr Union, ... such as workshops and competitions for ample networking, learning and collaborating opportunities. ...
Breaking Biology Technology: